[ad_1]
The World Well being Group (WHO) has granted emergency use approval for the Covid-19 vaccine made by the Serum Institute of India underneath license from US biotech agency Novavax. The jab is the ninth to be authorized by the physique.
In a press launch on Friday, the WHO stated that the granting of emergency use itemizing (EUL) to the vaccine, named Covovax, was an excellent step ahead in ongoing efforts to vaccinate extra individuals in lower-income international locations.
Learn extra
The shot is produced by the Serum Institute of India underneath license from Novavax, and the Covax vaccine-sharing initiative has already ordered some 350 million doses.
“This itemizing goals to extend entry notably in lower-income international locations, 41 of which have nonetheless not been capable of vaccinate 10% of their populations, whereas 98 international locations haven’t reached 40%,” Dr Mariangela Simao, the WHO’s assistant director basic for entry to medicines and well being merchandise, stated in an announcement.
The Novavax shot, a protein vaccine which makes use of expertise that has been employed for many years to guard individuals from hepatitis, shingles, and different viral infections, has demonstrated excessive ranges of efficacy (89.7% safety) in opposition to Covid-19 in trials. It requires two doses and is steady at refrigerated temperatures of between two and eight levels Celsius.
The model of the vaccine produced by Novavax itself is present process evaluations within the UK and EU.
The shot is the ninth to be authorized by the WHO. These already greenlit by the UN well being physique embody vaccines by Oxford/AstraZeneca, Pfizer/BioNTech, and Moderna.
[ad_2]
Source link
